These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2516402)

  • 41. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children.
    Bessho F; Hashizume K; Nakajo T; Kamoshita S
    J Pediatr; 1991 Aug; 119(2):237-41. PubMed ID: 1861208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urinary vanilmandelic acid and homovanillic acid: markers of two distinct cell populations in neuroblastoma?
    Mastrangelo R; Lasorella A; Iavarone A; Troncone L
    Pediatr Hematol Oncol; 1991; 8(4):379-81. PubMed ID: 1782120
    [No Abstract]   [Full Text] [Related]  

  • 43. Can a patient with neuroblastoma be diagnosed by a single urine sample collected randomly?
    Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
    Oncology; 1991; 48(1):31-3. PubMed ID: 1987496
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot study of screening for neuroblastoma in the north of England.
    Craft AW; Parker L; Dale G; McGill AC; Seviour JA; Bell S; Cole M; Smith J
    Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):337-41. PubMed ID: 1456400
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Laboratory techniques and neuroblastoma screening.
    Sawada T
    Lancet; 1988 Nov; 2(8620):1134-5. PubMed ID: 2903341
    [No Abstract]   [Full Text] [Related]  

  • 46. Simultaneous determination of vanillylmandelic acid, homovanillic acid and creatinine in urine by reversed-phase ion-pair chromatography.
    Tokuda T; Tokieda T; Anazawa A; Yoshioka M
    J Chromatogr; 1990 Sep; 530(2):418-23. PubMed ID: 2079515
    [No Abstract]   [Full Text] [Related]  

  • 47. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma.
    Tuchman M; Ramnaraine ML; Woods WG; Krivit W
    Pediatrics; 1987 Feb; 79(2):203-5. PubMed ID: 3808793
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serial measurement of urinary VMA and HVA levels from one infant: a study for neuroblastoma mass screening.
    Sawada T; Numata K; Hirata S
    J Pediatr Surg; 1992 Apr; 27(4):452-5. PubMed ID: 1522454
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Japanese experience of screening.
    Takeda T; Hatae Y; Nakadate H; Nishi M; Hanai J; Sato Y; Takasugi N
    Med Pediatr Oncol; 1989; 17(5):368-72. PubMed ID: 2796852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Characteristics of urinary excretion of vanilmandelic and homovanillic acids in cases of neuroblastoma during therapy].
    Lamedica G; Falcone R; De Bernardi B; Canini S
    Minerva Pediatr; 1978 Jan; 30(2):137-46. PubMed ID: 642879
    [No Abstract]   [Full Text] [Related]  

  • 51. Olive ingestion causing a false suspicion of relapsed neuroblastoma: A case of "oliveblastoma?".
    Flynn N; LeFebvre A; Messahel B; Hogg SL
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27248. PubMed ID: 29923309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Value of random urinary homovanillic acid and vanillylmandelic acid levels in the diagnosis and management of patients with neuroblastoma: comparison with 24-hour urine collections.
    Tuchman M; Morris CL; Ramnaraine ML; Bowers LD; Krivit W
    Pediatrics; 1985 Feb; 75(2):324-8. PubMed ID: 3969335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Letter: Reliable chemical diagnosis of neuroblastoma better than screening.
    Bray PF; Wu JT; Myers GG
    N Engl J Med; 1976 Jul; 295(4):230-1. PubMed ID: 1272359
    [No Abstract]   [Full Text] [Related]  

  • 54. Mass-screening of neuroblastoma using urine from infants by high-performance liquid chromatographic method: results of first (6th month) and second (14th month) screening.
    Takeda T; Shimada M; Nishi M; Hanai J; Kikuchi Y
    J Neurooncol; 1997 Jan; 31(1-2):165-70. PubMed ID: 9049845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of the diurnal variations in urinary homovanillic and vanillylmandelic acid excretion for the diagnosis and follow-up of patients with neuroblastoma.
    Tuchman M; Robison LL; Maynard RC; Ramnaraine ML; Krivit W
    Clin Biochem; 1985 Jun; 18(3):176-9. PubMed ID: 4039636
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 5-year (1990-1994) neuroblastoma screening feasibility study in France. Methodology and preliminary observations.
    Mathieu P; Frappaz D; Chauvin F; Combaret V; Vercherat M; Brunat-Mentigny M; David L; Esteve J; Favrot M; Fouillat V; Greffe J; Lasset C; Renaud P; Philip T
    Early Hum Dev; 1996 Sep; 46(1-2):177-96. PubMed ID: 9019414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Compliance in a screening program for neuroblastoma.
    Campion P; Woods WG; Lemieux B
    Prev Med; 1998; 27(4):590-6. PubMed ID: 9672953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determination of vanillylmandelic acid, vanillactic acid, and homovanillic acid in dried urine on filter-paper discs by high-performance liquid chromatography with coulometric electrochemical detection for neuroblastoma screening.
    Kinoshita Y; Yamada S; Haraguchi K; Takayanagi T; Mori Y; Takahashi T; Haruki E
    Clin Chem; 1988 Nov; 34(11):2228-30. PubMed ID: 3180413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Screening for neuroblastoma.
    Lancet; 1987 Nov; 2(8569):1204. PubMed ID: 2890821
    [No Abstract]   [Full Text] [Related]  

  • 60. Screening for neuroblastoma in North America. 2-year results from the Quebec Project.
    Woods WG; Tuchman M; Bernstein ML; Leclerc JM; Brisson L; Look T; Brodeur GM; Shimada H; Hann HL; Robison LL
    Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):312-9. PubMed ID: 1456396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.